conv.

All stories
HealthQuiet 10d · day 13

AstraZeneca's Etcamah fails late-stage breast cancer trial

The drug missed its primary endpoint for progression-free survival in combination with palbociclib, despite earlier FDA accelerated approval.

newest coverage 9d agosummary written 9d ago12 pieces NewswiresGoogle NewsMastodon

What to know

  • Etcamah failed its primary endpoint of improving progression-free survival in combination with palbociclib in a late-stage trial, showing only numerical improvement.
  • The drug had received FDA accelerated approval just the week prior for use with CDK4/6 inhibitors, raising questions about the basis for that approval.
  • AstraZeneca's stock dropped 3% in aftermarket trading on the announcement.

“AstraZeneca PLC announced Friday that its breast cancer drug Etcamah failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial.”

Investing.com · Investing.com News ↗

AstraZeneca Pharmaceutical company developing Etcamah

AstraZeneca's Etcamah fails late-stage breast cancer trial
Investing.com News

How it unfolded 2 developments, newest first · click a bar or a number to jump articles

Peak 5 pieces in 3h at Sep 14, 12 AM; 12 pieces over 13 days (11 articles · 1 post) Sep 11, 3 PM — 3 pieces · 3 articles — Newswires 3Sep 11, 6 PM — quietSep 11, 9 PM — quietSep 12, 12 AM — 1 piece · 1 article — Newswires 1Sep 12, 3 AM — quietSep 12, 6 AM — quietSep 12, 9 AM — quietSep 12, 12 PM — quietSep 12, 3 PM — quietSep 12, 6 PM — quietSep 12, 9 PM — quietSep 13, 12 AM — quietSep 13, 3 AM — quietSep 13, 6 AM — quietSep 13, 9 AM — quietSep 13, 12 PM — quietSep 13, 3 PM — quietSep 13, 6 PM — quietSep 13, 9 PM — quietSep 14, 12 AM — 5 pieces · 5 articles — Google News 5Sep 14, 3 AM — quietSep 14, 6 AM — 1 piece · 1 article — Newswires 1Sep 14, 9 AM — 2 pieces · 1 article · 1 post — Mastodon 1, Newswires 1Sep 14, 12 PM — quietSep 14, 3 PM — quietSep 14, 6 PM — quietSep 14, 9 PM — quietSep 15, 12 AM — quietSep 15, 3 AM — quietSep 15, 6 AM — quietSep 15, 9 AM — quietSep 15, 12 PM — quietSep 15, 3 PM — quietSep 15, 6 PM — quietSep 15, 9 PM — quietSep 16, 12 AM — quietSep 16, 3 AM — quietSep 16, 6 AM — quietSep 16, 9 AM — quietSep 16, 12 PM — quietSep 16, 3 PM — quietSep 16, 6 PM — quietSep 16, 9 PM — quietSep 17, 12 AM — quietSep 17, 3 AM — quietSep 17, 6 AM — quietSep 17, 9 AM — quietSep 17, 12 PM — quietSep 17, 3 PM — quietSep 17, 6 PM — quietSep 17, 9 PM — quietSep 18, 12 AM — quietSep 18, 3 AM — quietSep 18, 6 AM — quietSep 18, 9 AM — quietSep 18, 12 PM — quietSep 18, 3 PM — quietSep 18, 6 PM — quietSep 18, 9 PM — quietSep 19, 12 AM — quietSep 19, 3 AM — quietSep 19, 6 AM — quietSep 19, 9 AM — quietSep 19, 12 PM — quietSep 19, 3 PM — quietSep 19, 6 PM — quietSep 19, 9 PM — quietSep 20, 12 AM — quietSep 20, 3 AM — quietSep 20, 6 AM — quietSep 20, 9 AM — quietSep 20, 12 PM — quietSep 20, 3 PM — quietSep 20, 6 PM — quietSep 20, 9 PM — quietSep 21, 12 AM — quietSep 21, 3 AM — quietSep 21, 6 AM — quietSep 21, 9 AM — quietSep 21, 12 PM — quietSep 21, 3 PM — quietSep 21, 6 PM — quietSep 21, 9 PM — quietSep 22, 12 AM — quietSep 22, 3 AM — quietSep 22, 6 AM — quietSep 22, 9 AM — quietSep 22, 12 PM — quietSep 22, 3 PM — quietSep 22, 6 PM — quietSep 22, 9 PM — quietYesterday, 12 AM — quietYesterday, 3 AM — quietYesterday, 6 AM — quietYesterday, 9 AM — quietYesterday, 12 PM — quietYesterday, 3 PM — quietYesterday, 6 PM — quietYesterday, 9 PM — quietToday, 12 AM — quietToday, 3 AM — quietToday, 6 AM — quiet 12
Sep 12Sep 13Sep 14Sep 15Sep 16Sep 17Sep 18Sep 19Sep 20Sep 21Sep 22now · 7:49 AM ET
  1. 2

    AstraZeneca shares drop 3% on trial failure announcement

    The drugmaker's U.S.-listed shares dropped 3% in aftermarket trading following the announcement of the failed trial endpoint.

    • STAT

      AstraZeneca said that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors, a result that could limit the use of the medicine. https://www. statnews.com/2026/09/12/astraz eneca-breast-cancer-camizestrant-etcamah-serena-4-trail-failure/

      STATMastodon9d agoview on Mastodon ↗
  2. 1 day quiet
  3. 1

    Etcamah fails primary endpoint in late-stage trial

    AstraZeneca announced that Etcamah failed to meet the primary endpoint of improving progression-free survival when tested in combination with palbociclib in previously untreated patients with advanced breast cancer. The combination showed only a numerical improvement in this patient population.

    1. 3 outlets Breast cancer pill from AstraZeneca misses mark in pivotal trial

      first by STAT, 10d ago · also Hindustan Times, WSJ

      1 more headline

    2. 2 outlets first by Investing.com News, 12d ago · also Seeking Alpha · read ↗

    1 more claim →
  4. background

    FDA grants Etcamah accelerated approval for CDK4/6 inhibitor combinations — The U.S. Food and Drug Administration granted accelerated approval for AstraZeneca's Etcamah to be used alongside certain targeted cancer medicines known as CDK4/6 inhibitors.

Also covered reported alongside — the timeline has no entry for these yet

  1. 2 outlets AstraZeneca’s Etcamah flunks first-line breast cancer trial, adding to oral SERDs’ failure record

    first by Fierce Pharma, 10d ago · also FirstWord Pharma

    1 more headline

and 2 smaller pieces